Abstract
Abstract
Objective:
The aim of this research was to describe and investigate characteristics of patients who underwent surgical removal of the Essure® device (Bayer, Whippany, NJ). This device was the first transcervical micro insert device for permanent sterilization.
Materials and Methods:
A retrospective chart review was conducted at an academic hospital on patients undergoing surgical removal of the Essure device from 2014 to 2017.
Results:
A total of 69 patients underwent Essure removal—25 via laparoscopic hysterectomy, 38 via salpingectomy with cornual resection, and 6 via salpingectomy without cornual resection. The mean age of the subjects was 36.4 years (standard deviation [SD] = 7.2). The mean body mass index was 31.7 (SD = 7.3). The most-commonly reported past medical histories were anxiety (19/69) and depression (16/69). Thirty-eight patients had histories of prior surgeries, with cesarean section being reported most commonly (22/38). The most-frequently cited Essure-attributed symptoms were pelvic pain (63/69), bleeding (34/69), and bloating (15/69). When removal was requested, 58/69 patients had had the device in for >1 year and 44/69 patients reported onset of symptoms at time of placement. During the removal surgery, 59/69 patients had additional pelvic intraoperative findings; specifically, 43/69 had endometriosis, 24/69 had adhesions, 22/69 had adenomyosis, 8/69 had fibroids; and 7/69 had misplaced coils. The majority of fallopian tubes were normal/no pathologic alterations (35/69), with smaller subsets of patients having paratubal cysts (26/69) and fibrosis (5/69).
Conclusions:
Patients seeking removal of the Essure device might have coexisting pelvic pathology. Providers should be prepared to address any intraoperative pathology found.
Get full access to this article
View all access options for this article.